Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide Acetate 17 mg Depot in Prostate Cancer
NCT00630799Phase 3Terminated
- Sponsor
- GP Pharm
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by GP Pharm. Primary endpoint: Percent of successful patients achieving chemical castration at Day 168. Started May 2008; status: terminated.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00630799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630799.